Anthony Sauerwein, MD
Nuclear Cardiology · Moorestown, NJNPI 1750340857
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,608 of the $10,108 with a category attached, or 75.3%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $3,082 and has fallen 70.7% since, to $903 in 2025.
Across 437 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$2K
- Boston Scientific$2K
- Amgen$920
- Johnson & Johnson$882
- E.r. Squibb & Sons, L.L.C.$721
- Pfizer$668
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$2,50025%
- Food & beverage$7,60875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 9 | $2,119 |
| Boston Scientific | 39 | $2,038 |
| Amgen | 64 | $920 |
| Johnson & Johnson | 57 | $882 |
| E.r. Squibb & Sons, L.L.C. | 79 | $721 |
| Pfizer | 51 | $668 |
| Sanofi-aventis U.S. LLC | 5 | $551 |
| Novartis | 33 | $523 |
| Boehringer Ingelheim | 26 | $317 |
| AstraZeneca | 12 | $260 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $240 |
| Amarin Pharma, Inc. | 12 | $146 |
| Impulse Dynamics (USA) Inc. | 4 | $140 |
| Philips North America LLC | 7 | $120 |
| Merck | 6 | $93 |
| Atricure, Inc. | 1 | $93 |
| Kestra Medical Technology Services, Inc. | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Abbott | 1 | $31 |
| Abiomed | 1 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,108 in reported general payments places this provider in the 80th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 558 | $696,637 |
| XareltoRivaroxaban | 182 | $213,932 |
| JardianceEmpagliflozin | 44 | $50,619 |
| EntrestoSacubitril/Valsartan | 43 | $48,208 |
| Repatha SureclickEvolocumab | 36 | $42,693 |
| Praluent PenAlirocumab | 14 | $19,447 |
| BrilintaTicagrelor | 20 | $16,066 |
| Metoprolol Succinate | 572 | $9,158 |
| Atorvastatin Calcium | 559 | $7,020 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $5,640 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $4,695 |
| Ranolazine ErRanolazine | 23 | $3,435 |
| Amlodipine Besylate | 563 | $3,430 |
| Ezetimibe | 134 | $3,144 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 84 | $3,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $668 | $696,637558 claims |
| Johnson & JohnsonXarelto | $882 | $213,932182 claims |
| Boehringer IngelheimJardiance | $317 | $50,61944 claims |
| NovartisEntresto | $523 | $48,20843 claims |
| AstraZenecaBrilinta | $260 | $16,06620 claims |
| Esperion Therapeutics, Inc.Nexlizet | $2,119 | $4,69512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Moorestown
- Ralph RussoMoorestown$11K
- Samuel VentrellaMoorestown$7K
- Thomas GalskiMoorestown$6K
- Jay SussmanMoorestown$3K
- Antonio ValoneMoorestown$3K
- Pamela FazioMoorestown$2K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.